UBS Group’s Scinai Immunotherapeutics SCNI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1K | Buy |
396
+304
| +330% | +$1.5K | ﹤0.01% | 9662 |
|
|
2026
Q1 | $524 | Sell |
92
-83
| -47% | -$668 | ﹤0.01% | 9849 |
|
|
2025
Q4 | $1.25K | Buy |
175
+174
| +17,400% | +$1.98K | ﹤0.01% | 9652 |
|
|
2025
Q3 | $10 | Sell |
1
-1,205
| -100% | -$21K | ﹤0.01% | 10189 |
|
|
2025
Q2 | $27.5K | Sell |
1,206
-287
| -19% | -$7.22K | ﹤0.01% | 8223 |
|
|
2025
Q1 | $40.2K | Sell |
1,493
-856
| -36% | -$29.3K | ﹤0.01% | 7743 |
|
|
2024
Q4 | $78.6K | Buy |
2,349
+2,346
| +78,200% | +$80.6K | ﹤0.01% | 7024 |
|
|
2024
Q3 | $104 | Sell |
3
-18
| -86% | -$688 | ﹤0.01% | 9156 |
|
|
2024
Q2 | $586 | Hold |
21
| – | – | ﹤0.01% | 8854 |
|
|
2024
Q1 | $1.1K | Hold |
21
| – | – | ﹤0.01% | 8231 |
|
|
2023
Q4 | $1.26K | Buy |
21
+13
| +163% | +$894 | ﹤0.01% | 8359 |
|
|
2023
Q3 | $717 | Buy |
8
+5
| +167% | +$641 | ﹤0.01% | 8314 |
|
|
2023
Q2 | $431 | Sell |
3
-50
| -94% | -$8.64K | ﹤0.01% | 8238 |
|
|
2023
Q1 | $11.5K | Buy |
53
+50
| +1,667% | +$12.3K | ﹤0.01% | 7499 |
|
|
2022
Q4 | $888 | Sell |
3
-5
| -63% | -$3.76K | ﹤0.01% | 10044 |
|
|
2022
Q3 | $6K | Buy |
8
+3
| +60% | +$3.38K | ﹤0.01% | 9058 |
|
|
2022
Q2 | $5K | Sell |
5
-5
| -50% | -$6.86K | ﹤0.01% | 8927 |
|
|
2022
Q1 | $17K | Buy |
10
+3
| +43% | +$4.36K | ﹤0.01% | 7666 |
|
|
2021
Q4 | $16K | Buy |
7
+4
| +133% | +$8.26K | ﹤0.01% | 8178 |
|
|
2021
Q3 | $6K | Buy |
3
+1
| +50% | +$2.57K | ﹤0.01% | 8441 |
|
|
2021
Q2 | $5K | Buy |
+2
| New | +$6.22K | ﹤0.01% | 8565 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 9408 |
|
|
2020
Q3 | – | Sell |
-2
| Closed | -$43K | – | 8358 |
|
|
2020
Q2 | $43K | Buy |
+2
| New | +$32.2K | ﹤0.01% | 5987 |
|
|
2019
Q2 | – | Sell |
-1
| Closed | -$5K | – | 8117 |
|
|
2019
Q1 | $5K | Sell |
1
-2
| -67% | -$10.4K | ﹤0.01% | 7178 |
|
|
2018
Q4 | $14K | Sell |
3
-2
| -40% | -$10.8K | ﹤0.01% | 7049 |
|
|
2018
Q3 | $25K | Buy |
5
+4
| +400% | +$23.9K | ﹤0.01% | 6672 |
|
|
2018
Q2 | $8K | Sell |
1
-1
| -50% | -$6.47K | ﹤0.01% | 7269 |
|
|
2018
Q1 | $11K | Buy |
+2
| New | +$12.5K | ﹤0.01% | 6815 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 8001 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$3.64K | – | 7893 |
|
|
2016
Q2 | $5K | Buy |
+1
| New | +$3.69K | ﹤0.01% | 7133 |
|
|
2015
Q4 | – | Sell |
-4
| Closed | -$13K | – | 8540 |
|
|
2015
Q3 | $13K | Buy |
4
+1
| +33% | +$4.09K | ﹤0.01% | 7084 |
|
|
2015
Q2 | $13K | Buy |
+3
| New | +$14.1K | ﹤0.01% | 7266 |
|
Other funds holding SCNI
AC
VF
SG
XT
HF
UBS Group's SCNI Position: Q2 2026 in Review
UBS Group increased its Scinai Immunotherapeutics (SCNI) stake by 330% in Q2 2026, buying an estimated $1.5K and bringing the position to 396 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #9662.
UBS Group first reported a position in SCNI in Q2 2015 and has held it in 30 quarters since. The position peaked at $78.6K in Q4 2024. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.
- UBS Group held 396 shares of Scinai Immunotherapeutics worth $1K as of Q2 2026.
- UBS Group bought 304 Scinai Immunotherapeutics shares in Q2 2026, an estimated $1.5K.
- Scinai Immunotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9662 holding.
- UBS Group first reported a position in Scinai Immunotherapeutics in Q2 2015 and has held it in 30 quarters since.
- UBS Group's Scinai Immunotherapeutics position peaked at $78.6K in Q4 2024.
- 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.